Trial · NCT02064894
Oral Analgesic Utilization for CHildhood Musculoskeletal Injuries
NCT02064894, Not applicable, Completed, St. Justine's Hospital; results first posted 2017-08-03
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Oral Analgesic Utilization for CHildhood Musculoskeletal Injuries. Trials, record NCT02064894. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02064894
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Oral Analgesic Utilization for CHildhood Musculoskeletal Injuries
- NCT number
- NCT02064894
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 501 participants, actual
- Lead sponsor
- St. Justine's Hospital
- Conditions
- Musculoskeletal Injury
- Interventions
- oral morphine and oral ibuprofen, Oral morphine, Oral ibuprofen
- First posted
- 2014-02-17
- Last updated
- 2017-08-03
- Results first posted
- 2017-08-03
- Limitations and caveats
High attrition rate between the time of randomization and the 120 minutes following analgesic administration; The dose of oral morphine was within the recommended range, but higher doses have been used in other trials for MSK pain relief in children.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain Intensity - Percentage of Children Who Achieved VAS < 30 mm | 60 minutes post-analgesia | Percentage of participants which pain intensity has decreased under 30 mm on the VAS at 60 minutes. The Visual Analogue Scale is a 0 to 100 mm continuous scale measuring the pain intensity. Score of 0="No Pain"; Score of 100="Worst imaginable pain" |
| Secondary | Serious Adverse Event - Side Effects and Serious Adverse Events | 60, 90 and 120 minutes | To verify the occurence of any serious adverse event, such as respiratory depression or deep sedation, during all the time-periods of the study |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Pain Intensity - Percentage of Children Who Achieved VAS < 30 mm | 60 minutes post-analgesia | Percentage of participants | NUMBER | |
| SECONDARY | Serious Adverse Event - Side Effects and Serious Adverse Events | 60, 90 and 120 minutes | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group9
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Pain Intensity - Percentage of Children Who Achieved VAS < 30 mm | Oral Morphine and Oral Ibuprofen | 33.0 | 95% Confidence Interval 24.2 to 43.1 | Percentage of participants | |
| Pain Intensity - Percentage of Children Who Achieved VAS < 30 mm | Morphine and Placebo of Ibuprofen | 29.3 | 95% Confidence Interval 23.2 to 36.1 | Percentage of participants | |
| Pain Intensity - Percentage of Children Who Achieved VAS < 30 mm | Ibuprofen and Placebo of Morphine | 29.9 | 95% Confidence Interval 23.7 to 37.1 | Percentage of participants | |
| Serious Adverse Event - Side Effects and Serious Adverse Events | Oral Morphine and Oral Ibuprofen | Side effects | 6 | Participants | |
| Serious Adverse Event - Side Effects and Serious Adverse Events | Morphine and Placebo of Ibuprofen | Side effects | 39 | Participants | |
| Serious Adverse Event - Side Effects and Serious Adverse Events | Ibuprofen and Placebo of Morphine | Side effects | 38 | Participants | |
| Serious Adverse Event - Side Effects and Serious Adverse Events | Oral Morphine and Oral Ibuprofen | Serious adverse event | 0 | Participants | |
| Serious Adverse Event - Side Effects and Serious Adverse Events | Morphine and Placebo of Ibuprofen | Serious adverse event | 0 | Participants | |
| Serious Adverse Event - Side Effects and Serious Adverse Events | Ibuprofen and Placebo of Morphine | Serious adverse event | 0 | Participants |
Source ClinicalTrials.gov
Participant flow15
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Oral Morphine and Oral Ibuprofen | 99 | |
| Overall Study | STARTED | Morphine and Placebo of Ibuprofen | 201 | |
| Overall Study | STARTED | Ibuprofen and Placebo of Morphine | 201 | |
| Overall Study | Available at T-60 | Oral Morphine and Oral Ibuprofen | 91 | |
| Overall Study | Available at T-60 | Morphine and Placebo of Ibuprofen | 188 | |
| Overall Study | Available at T-60 | Ibuprofen and Placebo of Morphine | 177 | |
| Overall Study | Avalaible at T-90 | Oral Morphine and Oral Ibuprofen | 74 | |
| Overall Study | Avalaible at T-90 | Morphine and Placebo of Ibuprofen | 134 | |
| Overall Study | Avalaible at T-90 | Ibuprofen and Placebo of Morphine | 129 | |
| Overall Study | COMPLETED | Oral Morphine and Oral Ibuprofen | 56 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 participant flowAdverse events18
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nausea | Gastrointestinal disorders | Oral Morphine and Oral Ibuprofen | 0 | 91 | |
| other | Nausea | Gastrointestinal disorders | Morphine and Placebo of Ibuprofen | 11 | 188 | |
| other | Nausea | Gastrointestinal disorders | Ibuprofen and Placebo of Morphine | 7 | 177 | |
| other | Abdominal pain | Gastrointestinal disorders | Oral Morphine and Oral Ibuprofen | 0 | 91 | |
| other | Abdominal pain | Gastrointestinal disorders | Morphine and Placebo of Ibuprofen | 7 | 188 | |
| other | Abdominal pain | Gastrointestinal disorders | Ibuprofen and Placebo of Morphine | 7 | 177 | |
| other | Drowsiness | Nervous system disorders | Oral Morphine and Oral Ibuprofen | 0 | 91 | |
| other | Drowsiness | Nervous system disorders | Morphine and Placebo of Ibuprofen | 5 | 188 | |
| other | Drowsiness | Nervous system disorders | Ibuprofen and Placebo of Morphine | 4 | 177 | |
| other | Fatigue | General disorders | Oral Morphine and Oral Ibuprofen | 2 | 91 |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 adverse eventsAdverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Oral Morphine and Oral Ibuprofen | ||
| Total, all-cause mortality | Morphine and Placebo of Ibuprofen | ||
| Total, all-cause mortality | Ibuprofen and Placebo of Morphine | ||
| Total, other adverse events | Oral Morphine and Oral Ibuprofen | 6 | 91 |
| Total, other adverse events | Morphine and Placebo of Ibuprofen | 39 | 188 |
| Total, other adverse events | Ibuprofen and Placebo of Morphine | 38 | 177 |
| Total, serious adverse events | Oral Morphine and Oral Ibuprofen | 0 | 91 |
| Total, serious adverse events | Morphine and Placebo of Ibuprofen | 0 | 188 |
| Total, serious adverse events | Ibuprofen and Placebo of Morphine | 0 | 177 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 29021235 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02064894
GET https://conductscience.org/api/trials/v1/NCT02064894/registered